See more : Japan Real Estate Investment Corporation (8952.T) Income Statement Analysis – Financial Results
Complete financial analysis of MedRx Co., Ltd (4586.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedRx Co., Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- PT Arthavest Tbk (ARTA.JK) Income Statement Analysis – Financial Results
- Grandblue Environment Co., Ltd. (600323.SS) Income Statement Analysis – Financial Results
- Green Battery Minerals Inc. (GBMIF) Income Statement Analysis – Financial Results
- BlackBerry Limited (BB) Income Statement Analysis – Financial Results
- Kendrick Resources PLC (KEN.L) Income Statement Analysis – Financial Results
MedRx Co., Ltd (4586.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medrx.co.jp
About MedRx Co., Ltd
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 29.00M | 59.48M | 8.35M | 115.09M | 169.86M |
| Cost of Revenue | 3.00M | 2.62M | 2.26M | 3.91M | 5.25M |
| Gross Profit | 26.00M | 56.86M | 6.09M | 111.18M | 164.61M |
| Gross Profit Ratio | 89.66% | 95.60% | 72.90% | 96.60% | 96.91% |
| Research & Development | 737.00M | 921.00M | 794.00M | 967.00M | 1.51B |
| General & Administrative | 46.00M | 51.00M | 52.00M | 49.00M | 51.00M |
| Selling & Marketing | 175.00M | 183.00M | 218.00M | 188.00M | 227.00M |
| SG&A | 221.00M | 234.00M | 270.00M | 237.00M | 278.00M |
| Other Expenses | 1.00M | -6.02M | -2.00M | -13.44M | -8.29M |
| Operating Expenses | 959.00M | 1.16B | 1.07B | 1.24B | 1.79B |
| Cost & Expenses | 962.00M | 1.16B | 1.07B | 1.25B | 1.80B |
| Interest Income | 0.00 | 17.00K | 13.00K | 112.00K | 137.00K |
| Interest Expense | 0.00 | 1.88M | 1.47M | 367.00K | 4.91M |
| Depreciation & Amortization | 45.57M | 46.42M | 60.34M | 55.84M | 40.18M |
| EBITDA | -884.52M | -1.06B | -996.66M | -1.05B | -1.59B |
| EBITDA Ratio | -3,050.06% | -1,770.27% | -12,031.63% | -952.56% | -947.62% |
| Operating Income | -933.00M | -1.10B | -1.06B | -1.13B | -1.63B |
| Operating Income Ratio | -3,217.24% | -1,847.32% | -12,709.29% | -982.19% | -958.42% |
| Total Other Income/Expenses | 2.92M | -10.49M | 2.75M | 23.85M | 16.55M |
| Income Before Tax | -930.08M | -1.11B | -1.06B | -1.11B | -1.61B |
| Income Before Tax Ratio | -3,207.17% | -1,864.96% | -12,676.34% | -961.46% | -948.68% |
| Income Tax Expense | 2.00M | 1.84M | 1.36M | 8.08M | 4.88M |
| Net Income | -932.00M | -1.11B | -1.06B | -1.11B | -1.62B |
| Net Income Ratio | -3,213.79% | -1,868.04% | -12,692.61% | -968.48% | -951.56% |
| EPS | -26.82 | -43.81 | -49.62 | -68.61 | -134.32 |
| EPS Diluted | -26.82 | -43.81 | -49.62 | -68.61 | -134.32 |
| Weighted Avg Shares Out | 34.78M | 25.36M | 21.36M | 16.25M | 12.03M |
| Weighted Avg Shares Out (Dil) | 34.78M | 25.36M | 21.36M | 16.25M | 12.03M |
Source: https://incomestatements.info
Category: Stock Reports